Inventiva S.A.
IVA
Rank in Stocks
#10558
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Share Price
$3.29
Last synced: 2026-10-16
Market Cap
$776.14M
Change (1 day)
-2.29%
Change (1 year)
-18.09%
Country
FR
Trade Inventiva S.A. (IVA)
Category
Healthcare
Market Capitalization of Inventiva S.A.(IVA)
Market Cap: $776.14M
As of October 2026 Inventiva S.A. has a market cap of $776.14M. This makes Inventiva S.A. the world's 10558th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Market cap history of Inventiva S.A. from 2021 to 2026
IVA compared with Top 5 Most Popular stocks
